Murine transgenic cells lacking DNA topoisomerase IIβ are resistant to acridines and mitoxantrone: Analysis of cytotoxicity and cleavable complex formation

Molecular Pharmacology

Volumn 56, Issue 6, 1999, Pages 1309-1316

  Errington, F ^e   Willmore, E ^e   Tilby, M J ^e   Li, L ^a   Li, G ^a   Li, W ^b   Baguley, B C ^c   Austin, C A ^d  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b HARVARD UNIVERSITY   (United States)

^c UNIVERSITY OF AUCKLAND   (New Zealand)

^d NEWCASTLE UNIVERSITY   (United Kingdom)

^e NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACRIDINE DERIVATIVE; AMSACRINE; DNA TOPOISOMERASE (ATP HYDROLYSING); ETOPOSIDE; MITOXANTRONE;

ANIMAL CELL; ARTICLE; CELL SURVIVAL; COMPLEX FORMATION; CYTOTOXICITY; DRUG RESISTANCE; DRUG TARGETING; MOUSE; NONHUMAN; PRIORITY JOURNAL; TRANSGENIC MOUSE;

EID: 0032756225     PISSN: 0026895X     EISSN: None     Source Type: Journal    
DOI: 10.1124/mol.56.6.1309     Document Type: Article

References (40)

1. Austin CA and Marsh KL (1998) Eukaryotic DNA topoisomerase IIβ. Bioessays 20:215-226.
2. Austin CA, Marsh KL, Wasserman RA, Willmore E, Sayer PJ, Wang JC and Fisher LM (1995) Expression, domain structure, and enzymatic properties of an active recombinant human DNA topoisomerase IIβ. J Biol Chem 270:15739-15746.
3. Austin CA, Sng J, Patel S and Fisher LM (1993) Novel Hela topoisomerase II is the IIβ isoform: Complete coding sequence and homology with other type II topoisomerases. Biochim Biophys Acta 1172:283-291.
4. Baguely BC, Leteurtre F, Riou JF, Finlay GJ and Pommier Y (1997) A carbamate analogue of amsacrine with activity against non-cycling cells stimulates topoisomerase II cleavage at DNA sites distinct from those of amsacrine. Eur J Cancer 33:272-279.
5. Chen C, Fuscoe JC, Liu O and Belling MV (1996) Etoposide causes illegitimate V (D) J recombination in human lymphoid leukemic cells. Blood 86:2210-2218.
6. Dereuddre S, Delaporte C and Jacquemin-Sablon A (1997) Role of topoisomerase IIβ in the resistance of 9-OH-ellipticine-resistant Chinese hamster fibroblasts to topoisomerase II inhibitors. Cancer Res 57:4301-4308.
7. Dereuddre S, Frey S, Delaporte C and Jacquemin-Sablon A (1995) Cloning and characterization of full-length cDNAs coding for the DNA topoisomerase IIβ from Chinese hamster lung cells sensitive and resistant to 9-OH-ellipticine. Biochim Biophys Acta 1264:178-182.
8. Earnshaw WC, Halligan B, Cooke CA, Hech MMS and Liu LF (1985) Topoisomerase II is a structural component of mitotic chromosomes. J Cell Biol 100:1706-1715.
9. Feldhoff PW, Mirski SEL, Cole SPC and Sullivan DM (1994) Altered subcellular distribution of topoisomerase lia in a drug resistant human small cell lung cancer cell line. Cancer Res 54:756-762.
10. Giaccone G, Ark-Otte J, Scagliotti G, Capranico G, Valk P, Rubio G, Dalesio O Lopez R, Zunino F, Walboomers J and Pinedo HM (1995) Differential expression of DNA topoisomerases in non-small cell lung cancer and normal lung. Biochim Biophys Acta 1264:337-346.
11. Harker WG, Slade DL, Drake FH and Parr EL (1991) Mitoxantrone resistance in HL-60 leukemia cells: Reduced nuclear topoisomerase II catalytic activity and drug-induced DNA cleavage in association with reduced expression of the topoisomerase IIβ isoform. Biochemistry 30:9953-9961.
12. Harker WG, Slade DL, Parr RL, Feldoff PW, Sullivan DM and Holguin MH (1995) Alterations in the topoisomerase II α gene, messenger RNA, and subcellular protein distribution as well as reduced expression of the DNA topoisomerase II β enzyme in a mitoxantrone-resistant HL-60 human leukemia cell line. Cancer Res 55:1707-1716.
13. Harlow E and Lane D (1988) Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory Publications, Cold Spring Harbor, New York.
14. Heck MMS and Earnshaw WC (1986) Topoisomerase II: A specific marker for cell proliferation. J Cell Biol 103:2569-2581.
15. Heck MMS, Hittleman WN and Earnshaw WC (1988) Differential expression of DNA topoisomerase I and II during the eukaryotic cell cycle. Proc Natl Acad Sci USA 85:1086-1090.
16. Herzog CE, Holmes KA, Tuschong LM, Ganapathi R and Zwelling LA (1998) Absence of topoisomerase II β in an amsacrine-resistant human leukemia cell line with mutant topoisomerase II α. Cancer Res 58:5298-5300.
17. Holden JA, Rolfson DH and Wittwer CT (1992) The distribution of immunoreactive topoisomerase protein in human tissues and neoplasms. Oncol Res 4:157-166.
18. Houlbrook S, Addison CM, Davies SL, Carmichael J, Stratford IJ, Harris AL and Hickson ID (1995) Relationship between expression of topoisomerase II isoforms and intrinsic sensitivity to topoisomerase II inhibitors in breast cancer cell lines. Br J Cancer 72:1454-1461.
19. Lee M, Wang JC and Beran M (1992) Two independent amsacrine-resistant human myeloid leukemia cell lines share an identical point mutation in the 170 kDa form of human topoisomerase II. J Mol Biol 223:837-843.
20. Long BH, Wang L, Lorico A, Wang RCC, Brattain MG and Casazza AM (1991) Mechanisms of resistance to etoposide and teniposide in acquired resistant human colon and lung carcinoma cell lines. Cancer Res 51:5275-5284.
21. Lorico A, Rappa G, Srimatkandada S, Catapano CV, Fernandes DJ, Germino JF and Sartorelli AC (1995) Increased rate of adenine triphosphate-dependent etoposide (VP-16) efflux in a murine leukemia cell line over expressing the multidrug resistance-associated protein (MRP) gene. Cancer Res 56:4352-4360.
22. Meczes EL, Marsh KL, Fisher LM, Rogers MP and Austin CA (1997) Complementation of temperature-sensitive topoisomerase II mutations in Saccharomyces cerevisiae by a human TOP2β construct allows the study of topoisomerase IIβ inhibitors in yeast. Cancer Chemother Pharmacol 39:367-375.
23. Meyer KN, Kjeldsen E, Straub T, Knudsen BR, Hickson ID, Kikuchi A, Kreipe H and Boege F (1997) Cell cycle-coupled relocation of type I and II topoisomerases and modulation of catalytic enzyme activities. J Cell Biol 136:775-788.
24. Mirski SEL and Cole SPC (1995) Cytoplasmic localisation of a mutant M, 160,000 topoisomerase II α is associated with the loss of putative bipartite nuclear localisation signals in a drug-resistant human lung cancer cell line. Cancer Res 55: 2129-2134.
25. Mirski SEL, Evans CD, Almquist KC, Slovak ML and Cole SPC (1993) Altered topoisomerase IIα in a drug-resistant small cell lung cancer cell line selected in VP-16. Cancer Res 53:4866-4873.
26. Moreland N, Finlay GJ, Dragunow M, Holdaway KM and Baguley BC (1997) Cellular responses to methyl-N-[4-(9-acridinylamino)-2-methoxyphenyl] carbatamate hydrochloride, an analogue of amsacrine active against non-proliferating cells. Eur J Cancer 33:1668-1676.
27. Moses K, Harris AL and Durkacz BW (1988) Synergistic enhancement of 6-thioguanine cytotoxicity by ADP-ribosyltransferase inhibitors. Cancer Res 48:5650-5654.
28. Osheroff N (1989) Effect of antineoplastic agents on the DNA cleavage/religation of eukaryotic topoisomerase II: Inhibition of DNA religation by etoposide. Biochemistry 28:6157-6160.
29. Perrin D, Hille B and Hill BT (1998) Differential sensitivities of recombinant human topoisomerase II α and β to various classes of topoisomerase II-interacting agents. Biochem Pharmacol 56:503-507.
30. Pommier Y (1997) DNA topoisomerase II inhibitors, in Cancer Therapeutics: Experimental and Clinical Agents (Teicher BA ed) pp 153-174, Humana Press, Totowa, New Jersey.
31. Pommier Y, Zwelling LA, Kao-Shan C, Whang-Peng J and Bradley MO (1985a) Correlations between intercalator-induced DNA strand breaks and sister chromatid exchanges, mutations, and cytotoxicity in Chinese hamster cells. Cancer Res 45:3143-3149.
32. Prosperi E, Negri G, Marchese G and Astaldi Ricotti GCB (1994) Expression of 170kDa and 180kDa isoforms of DNA topoisomerase II in resting and proliferating human lymphocytes. Cell Prolif 27:257-267.
33. Son YS, Suh JM, Ahn SH, Kim JC, Yi JY, Hur KC, Hong W, Muller MT and Chung IK (1998) Reduced activity of topoisomerase II in an Adriamycin-resistant human stomach-adenocarcinoma cell line. Cancer Chemother Pharmacol 41:353-360.
34. Suzuki H, Tarumoto Y and Ohsawa M (1997) Topoisomerase II inhibitors fail to induce chromosome-type aberrations in etoposide-resistant cells: Evidence for essential contribution of the cleavable complex formation to the induction of chromosome-type aberrations. Mutagenesis 12:29-33.
35. Tan KB, Dorman TE, Falls KM, Chung TDY, Mirabelli CK, Crooke ST and Mao J (1992) Topoisomerase IIα and topoisomerase IIβ genes: Characterisation and mapping to human chromosome 17 and 3, respectively. Cancer Res 52:231-234.
36. Turley H, Comley M, Houlbrook S, Nozaki N, Kikuch A, Hickson ID, Gatter K and Harris AL (1997) The distribution and expression of the two isoforms of DNA topoisomerase II in normal and neoplastic human tissues. Br J Cancer 75:1340-1346.
37. Wang JC (1996) DNA topoisomerases. Annu Rev Biochem 65:635-692.
38. Willmore E, Frank AJ, Padget K, Tilby MJ and Austin CA (1998) Etoposide targets topoisomerase IIα and IIβ in leukemic cells: Isoform-specific cleavable complexes visualised and quantified in situ by a novel immunofluorescence technique. Mol Pharmacol 53:78-85.
39. 4. Br J Cancer 74:1869-1876.
40. Zwelling LA, Estey E, Bakic M, Silberman L and Chan D (1987) Topoisomerase II as a target of antileukemic drugs. Natl Cancer Inst Monogr 4:79-82.